Artelo Biosciences, Inc. (ARTL) vs GlucoTrack, Inc. (GCTK)
A side-by-side comparison of Artelo Biosciences, Inc. and GlucoTrack, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARTL
Artelo Biosciences, Inc.
$3.70HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
GCTK
GlucoTrack, Inc.
$1.12HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT
Total return — ARTL vs GCTK
growth of $100 · dividends reinvested · last 7yARTL -99.9% (-63.1%/yr)GCTK -100.0% (-83.6%/yr)ARTL compounded faster over this window
Log scale — wide-divergence pair
ARTL GCTK
ARTL vs GCTK: by the numbers
- •ARTL is the larger company ($1M vs $889929 market cap).
Metrics side by side
Valuation
| Metric | ARTL | GCTK |
|---|---|---|
| P/B ratio | 0.29 | N/A |
Profitability
| Metric | ARTL | GCTK |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -253.57% | N/A |
| ROIC | -219.36% | N/A |
Growth (annualized)
| Metric | ARTL | GCTK |
|---|---|---|
| Total return CAGR (5Y) | -64.27% | -92.60% |
Frequently asked
- How have ARTL and GCTK total returns compared?
- Over the past 5 years, ARTL delivered -64.27% and GCTK delivered -92.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.